“
Spectroscopy Focus
LCMS: From Pharmacokinetics to Metabolomics My team is involved in drug metabolism and pharmacokinetics of novel chemical entities and in the clinical pharmacokinetic evaluation of some of our agents, which have reached Phase I/II clinical trials at The Royal Marsden Hospital...
Bernie Monaghan (BM): Could you tell us a little about the unit and group in which you work at Sutton?
Florence Raynaud (FR): I work at The Institute of Cancer Research (ICR) in the Section of Cancer Therapeutics. Our mission is to discover and develop new drugs to treat cancer. We have an impressive track record in drug discovery in oncology as four compounds (melphalan, chlorambucil, carboplatin and ralitrexed) originating from the ICR have gained regulatory approval. In addition, we have several compounds in late clinical development (abiraterone, satraplatin and picoplatin). Six of our compounds are in early phase I/II clinical evaluations. They include conventional antiproliferative agents that are selectively transported to tumours and molecularly targeted agents such as HSP90, HDAC and PI3K inhibitors. These compounds have been licensed to pharmaceutical companies such as Novartis, Roche, Genentech and Onyx pharmaceuticals and some of them have been developed in partnership with biotechnology companies. We have an exciting pipeline which includes PKB inhibitors already licensed to Astra Zeneca, while B-RAF inhibitors, CHK1 and Aurora kinase inhibitors are all at licensing stage.
My team is involved in drug metabolism and pharmacokinetics of novel chemical entities and in the clinical pharmacokinetic evaluation of some of our agents, which have reached Phase I/II clinical trials at The Royal Marsden Hospital. In addition, we are interested in the identification of novel biomarkers by LCMS metabolomics. We are focusing on the exploration of the exo-metabolome to circumvent difficulties in obtaining tumour specimens. Tumours are often not accessible, serial biopsies are invasive and, at best, only pre-treatment samples and post- treatment biopsies are obtainable. Circulating biomarkers are, therefore, highly desirable. We have so far initiated preclinical studies to evaluate the potential of metabolomics in identifying metabolomic biomarkers of signal transduction inhibitors. This is essential if you are developing a targeted agent as you have to prove, in the clinical context, that the compound modulated its target. We focus particularly on the inhibitors that we have developed in the Cancer Research UK Centre for Cancer Therapeutics at the ICR and which we have in clinical trials at The Royal Marsden hospital.
BM: Which manufacturers Instruments do you use currently? Are there any technological reasons for making these choices?
FR: We have seven liquid chromatography mass spectrometry instruments in the laboratory, from a range of manufacturers (Agilent Technologies, AB-Sciex, Thermo- Scientific and Waters Corporation). We have four triple quadrupoles (including one hybrid triple quadrupole linear ion trap), one ion trap and two quadrupole time of flight.
Chelsea Site, Central London
Pharmacokinetic and Metabolomic Laboratory Sutton Site, Surrey Research Sections: Basic, Translational and Clinical Author Details:
Dr. Florence Raynaud, The Institute for Cancer Research, Sutton UK Group Leader Pharmacokinetics and Metabolomics Cancer Research UK Centre for Cancer Therapeutics
The Institute of Cancer Research Sutton, Surrey, UK Email:
florence.raynaud@icr.ac.uk
Biochemistry, Breakthrough Breast Cancer Centre, Cancer Genetics, Cancer Therapeutics, Cell and Molecular Biology, Clinical Research, Clinical Magnetic Resonance Research, Gene Function and Regulation, Epidemiology, Haemato-oncology, Medicine, Molecular Carcinogenesis, Paediatric Oncology, Physics, Radiotherapy, Structural Biology
We are at a really exciting crossroad in oncology drug development as many compounds are targeting molecular abnormalities that drive cancer. This means that drug administration can be optimised by evaluating the target modulation rather than the maximum tolerability. In addition, it may be possible to select the patients that are most likely to respond to treatment, which leads to personalised therapy. This requires a large investment in biomarker development and analysis.
Our major source of research funding is through a Cancer Research UK program grant to the Centre for Cancer Therapeutics. This grant is peer reviewed every five years and has provision for some capital equipment purchase and associated maintenance costs. We operate in a cost contained environment and have a duty to deliver value for money from all our equipment. Our choice of instrumentation is therefore crucial to our work and to assist us in the delivery of future clinical candidates. Our instruments are extensively tested for all our applications (quantitative and qualitative) during demonstrations by manufacturers and evaluated for affordability. We keep our instruments running until they are no longer functional or no longer supported; we are therefore looking for robustness, in addition to low maintenance costs. As an example, we recently donated a 17-year-old instrument to a university for student training.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
